Life-saving therapeutics continue to grow more costly to discover. At the same time, recent advances in using machine learning for the life sciences and medicine are extraordinary. Are we on the verge of a paradigm shift in biotech? This week on the podcast, a pioneer in AI, Daphne Koller, joins Sarah Guo and Elad Gil on the podcast to help us explore that question. Daphne is the CEO and founder of Insitro — a company that applies machine learning to pharma discovery and development, specifically by leveraging “induced pluripotent stem cells.” We explain Insitro’s approach, why they’re focused on generating their own data, why you can’t cure schizophrenia in mice, and how to design a culture that supports both research and engineering. Daphne was previously a computer science professor at Stanford, and co-founder and co-CEO of edutech company Coursera. Show Links:

Insitro - About